CKlife sciences (00775) announced that the group expects that the shareholders' profits for the six months ending on June 30, 2024, will decrease significantly compared to the six months ending on June 30, 2023. The expected decrease exceeds what was reported in the company's 2023 annual report and is attributed to the continued high cost of finance, which has had an impact on the group's overall surplus during the reporting period.
Changjiang Life Sciences (00775) has announced that the shareholders' attributable profit for the six months ending June 30, 2024 is expected to decrease significantly compared to the six months ending June 30, 2023. The expected decrease is higher than what was reported in the company's 2023 annual report and is due to the continuing high finance cost that has affected the group's overall surplus during the reporting period. During the reporting period, the group's healthcare product business has remained stable, but the agriculture-related business has been under pressure.